Research analysts at StockNews.com initiated coverage on shares of Cytosorbents (NASDAQ:CTSO - Get Free Report) in a report issued on Tuesday. The firm set a "hold" rating on the medical research company's stock.
Separately, D. Boral Capital reaffirmed a "buy" rating and issued a $10.00 target price on shares of Cytosorbents in a research report on Tuesday, February 25th. Two research analysts have rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $4.67.
Read Our Latest Stock Analysis on Cytosorbents
Cytosorbents Price Performance
Cytosorbents stock opened at $1.13 on Tuesday. The firm has a fifty day moving average of $1.06 and a 200-day moving average of $1.05. Cytosorbents has a 52-week low of $0.70 and a 52-week high of $1.61. The company has a quick ratio of 1.58, a current ratio of 1.97 and a debt-to-equity ratio of 1.06. The firm has a market capitalization of $61.79 million, a P/E ratio of -3.14 and a beta of 0.78.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently made changes to their positions in the stock. Geode Capital Management LLC lifted its position in Cytosorbents by 7.5% in the third quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company's stock worth $701,000 after purchasing an additional 32,415 shares during the period. Skylands Capital LLC raised its stake in shares of Cytosorbents by 1.0% in the 4th quarter. Skylands Capital LLC now owns 2,781,622 shares of the medical research company's stock worth $2,531,000 after buying an additional 26,195 shares in the last quarter. Millennium Management LLC acquired a new stake in shares of Cytosorbents in the fourth quarter valued at $30,000. Northern Trust Corp boosted its stake in Cytosorbents by 22.3% during the fourth quarter. Northern Trust Corp now owns 91,560 shares of the medical research company's stock valued at $83,000 after buying an additional 16,701 shares in the last quarter. Finally, Raymond James Financial Inc. bought a new position in Cytosorbents during the fourth quarter valued at about $99,000. 32.87% of the stock is currently owned by institutional investors.
About Cytosorbents
(
Get Free Report)
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Cytosorbents, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cytosorbents wasn't on the list.
While Cytosorbents currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
